AMCP Nexus 2022 Panel Explores Utilization Management of High-Price Treatments for Payers

New therapies for rare and orphan diseases have greatly improved in recent years, greatly improving outcomes for millions of patients. However, these treatments are often expensive, with 20% of drug spending going toward orphan drugs. In a panel at last week’s Academy of Managed Care Pharmacy (AMCP) Nexus 2022, speakers talked about how improved utilization management strategies could help optimize treatment prioritization for expensive therapies.

According to Amy Ware, Director at Specialty Clinical Solutions, “Continued growth like this among high cost and orphan drugs is why worldwide drug sales are forecast to grow at a compound annual rate of 12.3% from 2019 to 2024, which is approximately double the rate forecast for the nonorphan drug market,”

To read more, click here.

(Source: AJMC, October 15^th, 2022)